Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes
Mrinal M. Patnaik(Mayo Clinic in Arizona), Eric Padron(Moffitt Cancer Center), Rebecca R. Laborde(Mayo Clinic), Terra L. Lasho(Mayo Clinic), Christy M. Finke(Mayo Clinic), Curtis A. Hanson(Mayo Clinic), Janice M. Hodnefield(Mayo Clinic in Arizona), Ryan A. Knudson(Mayo Clinic), Rhett P. Ketterling(Mayo Clinic), Aref Al‐Kali(Mayo Clinic in Arizona), Animesh Pardanani(Mayo Clinic), Najla Al Ali(Moffitt Cancer Center), R S Komroji(Moffitt Cancer Center), A Tefferi(Mayo Clinic)
Cited by 218
Abstract
Related Papers
Monosomal Karyotype in Acute Myeloid Leukemia: A Better Indicator of Poor Prognosis Than a Complex Karyotype
Dimitri Breems, Wim L.J. van Putten, Georgine E. de Greef et al.|Journal of Clinical Oncology|2008|576
Mutations of polycomb‐associated gene <i>ASXL1</i> in myelodysplastic syndromes and chronic myelomonocytic leukaemia
Véronique Gelsi‐Boyer, Virginie Trouplin, José Adélaı̈de et al.|British Journal of Haematology|2009|555